NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate,Clinical Cancer Research

当前位置： X-MOL 学术 › Clin. Cancer Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate
Clinical Cancer Research ( IF 11.5 ) Pub Date : 2021-09-15 , DOI: 10.1158/1078-0432.ccr-21-1807
Min Yuen Teo ₁ , Jonathan E Rosenberg ₁

Affiliation

Nectin-4 is the target for enfortumab vedotin, a novel antibody–drug conjugate. NECTIN4 gene expression differs considerably across different molecular subtypes and is shown to be important for enfortumab vedotin efficacy. See related article by Chu et al., [p. 5123][1] [1]: /lookup/volpage/27/5123?iss=18

中文翻译：

膀胱癌中的 NECTIN4 异质性和分子多样性：解构抗体-药物偶联物的活性

Nectin-4 是新型抗体-药物偶联物 enfortumab vedotin 的靶标。NECTIN4 基因表达在不同分子亚型之间存在显着差异，并且被证明对 enfortumab vedotin 功效很重要。参见 Chu 等人的相关文章，[p. 5123][1][1]：/lookup/volpage/27/5123?iss=18

更新日期：2021-09-15

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>